Japanese drugmaker Eisai has aligned itself with France's Paoli Calmettes Institute to spotlight potential oncology therapies.
Biogen has been adding significantly to its manufacturing network lately. Now, it has decided, it is time to subtract.
Japan's Eisai has notched up solid Phase II results for oncology treatment Lenvima plus everolimus, the company said, citing an article on the trial results published in Lancet Oncology, putting it closer to capitalizing on a breakthrough therapy designation from the U.S. FDA for the drug to treat advanced and/or metastatic renal cell carcinoma.
With the self-proclaimed goal of becoming the country's largest gastrointestinal specialty drugmaker, Japan's Eisai and the pharmaceutical subsidiary of Ajinomoto said they will form a 60-40 joint venture with Eisai taking the majority position.
Japan's Eisai said it will present a series of clinical results on Lenvima (lenvatinib) and Halaven (eribulin), among other papers, at the European Cancer Congress, as the company works to grow its key oncology business.
Presumably hands were shaken and lawyers and executives read the fine print, putting a collaboration on anti-obesity drug Contrave between Japan's Takeda Pharmaceuticals and San Diego-based Orexigen Therapeutics back on track after a tussle broke out in May over the termination of a trial that opened up other issues in the partnership.
Eisai has struggled since falling off the patent cliff in 2010, when its blockbuster Alzheimer's med Aricept lost patent protection and sales took a hit. The company is looking to new meds to add salve to the wound, and a better-than-expected launch for its cancer hopeful Lenvima could be exactly what the doctor ordered.
An analysis by AdverseEvents shows the new generation of obesity meds are holding their own, safety-wise. Still, postmarketing data flag some serious cardiovascular and neuropsychiatric side effects that are worth monitoring, the healthcare informatics firm says.
Eisai has been whittling down its U.S. workforce as part of broader cost-cutting moves in the face of a tough patent cliff go. Now the Japanese drugmaker will trim another 135 people from its payroll with the sale of a manufacturing facility in North Carolina to drug development partner Biogen.
Dieting and exercise to lose weight is more effective when done with support--and weight-loss drugmakers have taken that to heart in marketing their treatments. But according to a recent Journal of Public Policy & Marketing article, lifestyle support isn't enough. Drugmakers may want to look to their advertising pitches, too.